A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Infectious Diseases

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/infdis/jiw077PMID 26917574PMCID PMC4907409
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preexposure Prophylaxis for the Prevention of HIV

  2018cited by this paper
• Models for Predicting Effective HIV Chemoprevention in Women

  2015cited by this paper
• From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity

  2015influential reference
• Tenofovir-based preexposure prophylaxis for HIV infection among African women.

  2015cited by this paper
• Herpes simplex virus type-2 stimulates HIV-1 replication in cervical tissues: implications for HIV-1 transmission and efficacy of anti-HIV-1 microbicides

  2014cited by this paper
• HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention

  2014cited by this paper
• A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate

  2014cited by this paper
• Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.

  2014influential reference
• R: A language and environment for statistical computing.

  2014cited by this paper
• Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues

  2014influential reference
• Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.

  2014cited by this paper
• Female Sex Hormone Regulation of Tenofovir-diphosphate in Human Female Reproductive Tract (FRT) Cells in Culture

  2014cited by this paper
• Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue

  2013cited by this paper
• Ex vivo models of HIV sexual transmission and microbicide development.

  2012cited by this paper
• Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

  2012cited by this paper
• Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

  2012cited by this paper
• Preexposure prophylaxis for HIV infection among African women.

  2012cited by this paper
• Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men

  2012influential reference
• Animal models for HIV/AIDS research

  2012cited by this paper
• HIV transmission.

  2012cited by this paper
• Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

  2012cited by this paper
• Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission

  2011influential reference
• Natural Substrate Concentrations Can Modulate the Prophylactic Efficacy of Nucleotide HIV Reverse Transcriptase Inhibitors

  2011cited by this paper
• Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.

  2011cited by this paper
• Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

  2010cited by this paper
• HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention

  2010cited by this paper
• Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.

  2009cited by this paper
• HIV Transmission

  2004cited by this paper
• Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV Infection

  2004cited by this paper
• Metabolism of Tenofovir and Didanosine in Quiescent or Stimulated Human Peripheral Blood Mononuclear Cells

  2003cited by this paper
• The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.

  2002cited by this paper
• Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy

  2002cited by this paper
• Pharmacodynamic interaction of recombinant human interleukin-10 and prednisolone using in vitro whole blood lymphocyte proliferation.

  2002cited by this paper
• Intestinal lymphatic drug transport: an update.

  2001cited by this paper
• Reproducible assessment of vaginal and rectal mucosal and skin blood flow: laser doppler fluximetry of the pelvic microcirculation.

  2000cited by this paper
• Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine against Drug-Susceptible and Drug-Resistant Human Immunodeficiency Virus Isolates

  1999cited by this paper
• A method for estimating and testing area under the curve in serial sacrifice, batch, and complete data designs.

  1999cited by this paper
• Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1

  1998cited by this paper
• Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.

  1995influential reference
• Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

  1995influential reference
• Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.

  1994cited by this paper
• Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells.

  1993cited by this paper
• Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression

  1989cited by this paper

• Genital tract infections, antiretroviral treatment and HIV-1 viral load in early postpartum women: : implications for sexual and breastfeeding HIV transmission

  2026cites this paper
• Pharmacokinetics of Dolutegravir, nucleoside analogues, and intracellular metabolites using plasma separation cards: A comparative analysis with traditional sampling methods in healthy volunteers

  2026influential citation
• Biomedical Interventions for HIV Prevention and Control: Beyond Vaccination

  2025cites this paper
• The Real-World Effectiveness of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Adults in Alberta, Canada: A Retrospective Population-Based Cohort Study

  2025cites this paper
• Acidic Nanoparticles Prevent HIV Pre‐Exposure Prophylaxis (PrEP)‐Induced Oligodendrocyte Impairments by Restoring Lysosomal pH in Adolescent Models

  2025cites this paper
• On-Demand Dosing of HIV Preexposure Prophylaxis for Women: Has Their Time Finally Come?

  2025cites this paper
• Drug transporter mRNA expression and genital inflammation in South African women on oral pre-exposure prophylaxis (PrEP)

  2025cites this paper
• Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV — CDC Recommendations, United States, 2025

  2025cites this paper
• Exploring potential drug−drug interactions between masculinizing hormone therapy and oral pre‐exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open‐label pharmacokinetic study in Thailand

  2025cites this paper
• Are Sex-Specific Cutoffs Needed With a Next-Generation Urine Tenofovir Lateral Flow Assay for Antiretroviral Adherence Monitoring?

  2025cites this paper
• Improving Participation in HIV Preexposure Prophylaxis via an Informatics Approach-a Process-Improvement Project.

  2025cites this paper
• HIV Pharmacology Data Repository: Setting the New Information‐Sharing Standard for Clinical and Preclinical Pharmacokinetic Studies

  2025cites this paper
• Event-driven PrEP beyond cisgender men who have sex with men.

  2025cites this paper
• Poor Oral HIV Pre-Exposure Prophylaxis (PrEP) Persistence in an Integrated PrEP/STI Program in Malawi.

  2025cites this paper
• Dosing forgiveness of oral PrEP for cisgender women remains uncertain

  2025cites this paper
• Assessing the Impact of Digital Communication Tools on Oral PrEP Adherence: A Systematic Review and Meta-analysis

  2025cites this paper
• Recommendations for interpreting intraerythrocytic tenofovir-diphosphate and emtricitabine-triphosphate for PrEP adherence assessment.

  2025cites this paper
• Hormones, microbes, and PrEP drugs in the female genital tract

  2025cites this paper
• What drives adolescent girls and young women's decisions to persist on PrEP? Results of a comparative qualitative study from a DREAMS program in western Kenya.

  2025cites this paper
• Performance of Adherence Measures for Oral, Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Systematic Review

  2025cites this paper
• Driving progress towards PrEP equity: Key changes in the 2025 BASHH/BHIVA UK PrEP guidelines

  2025cites this paper
• The female microbiome in HIV prevention, pathogenesis, and treatment.

  2025cites this paper
• Heterogeneous antiretroviral drug exposure in male and female genital tract tissues.

  2025cites this paper
• Understanding PrEP misconceptions and their impact on PrEP initiation and use among pregnant and lactating women in Malawi

  2025cites this paper
• Oral PrEP Use by Transgender Men in Uganda: A Multi-method Evaluation.

  2025cites this paper
• Background HIV Incidence in PURPOSE 1 and 2 PrEP Trials

  2025cites this paper
• Female genital tract host factors and tenofovir and lamivudine active metabolites.

  2024cites this paper
• HIV pre-exposure prophylaxis use during periods of unprotected sex among female sex workers in Tanga city, Tanzania: a control arm analysis of the pragmatic quasi-experimental trial

  2024cites this paper
• The relationship between gender and pharmacology

  2024cites this paper
• Incentivizing adherence to pre-exposure prophylaxis for HIV prevention: a randomized pilot trial among male sex workers in Mexico

  2024cites this paper
• Perceptions and Acceptance of a Prophylactic Vaccine for Human Immunodeficiency Virus (HIV): A Qualitative Study

  2024cites this paper
• Adult Human Brain Tissue Cultures to Study NeuroHIV

  2024influential citation
• A pilot program of HIV pre-exposure prophylaxis in Thai youth

  2024cites this paper
• Tenofovir Activation Is Diminished in the Brain and Liver of Creatine Kinase Brain-Type Knockout Mice.

  2024cites this paper
• Insights into the molecular interactions between urease subunit gamma from MRSA and drugs: an integrative approach by STD-NMR and molecular docking studies

  2024cites this paper
• HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.

  2024cites this paper
• A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation

  2024cites this paper
• HIV Pre-exposure Prophylaxis.

  2024cites this paper
• Antiretroviral (ARV) Properties Dictate Long-Acting Release and Tissue Partitioning Behaviors in Multidrug Subcutaneous Implants.

  2024cites this paper
• Person-centered pre-exposure prophylaxis: the next wave of innovation in HIV prevention.

  2024cites this paper
• Updated guidelines on HIV post‐exposure prophylaxis: continued efforts towards increased accessibility

  2024cites this paper
• Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review

  2024cites this paper
• Shifting the Narrative of Preexposure Prophylaxis Adherence Counseling for Cisgender Women.

  2024cites this paper
• Feasibility and Acceptability of a mHealth Patient Navigation Intervention to Increase Pre-Exposure Prophylaxis Uptake in Racially and Ethnically Diverse Sexual and Gender Minority Youth in Los Angeles (PrEPresent): Pilot Randomized Controlled Trial

  2024cites this paper
• Establishing adherence–concentration–efficacy thresholds of TDF–FTC pre-exposure prophylaxis for HIV prevention in African women: a protocol for the Women TDF–FTC Benchmark Study

  2024cites this paper
• A Scoping Review of Oral Pre-exposure Prophylaxis for Cisgender and Transgender Adolescent Girls and Young Women: What Works and Where Do We Go from Here?

  2023cites this paper
• Preventing HIV and achieving pregnancy among HIV sero-different couples: Pilot study of a safer conception intervention in Zimbabwe

  2023cites this paper
• Personalizing prevention: Advances in pharmacotherapy for HIV prevention

  2023cites this paper
• Mass spectrometry imaging of hair identifies daily maraviroc adherence in HPTN 069/ACTG A5305

  2023cites this paper
• Pre‐exposure prophylaxis adherence and discontinuation at an urban pre‐exposure prophylaxis program in Atlanta, Georgia

  2023cites this paper
• Synthesis of protective oral PrEP adherence levels in cisgender women using convergent clinical- and bottom-up modeling

  2023influential citation
• A Novel Algorithm to Improve PrEP Adherence Monitoring Using Dried Blood Spots

  2023cites this paper
• High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study

  2023cites this paper
• Uptake and continuation of HIV pre‐exposure prophylaxis among women of reproductive age in two health facilities in Kisumu County, Kenya

  2023cites this paper
• Updating the adherence-response for oral F-TDF for PrEP among cisgender women.

  2023cites this paper
• Breaking down relationship barriers to increase PrEP uptake and adherence among adolescent girls and young women in Kenya: safety and preliminary effectiveness results from a pilot cluster‐randomized trial

  2023cites this paper
• Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence

  2023cites this paper
• Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women

  2023influential citation
• Preferences for Long-Acting PrEP Products Among Women and Girls: A Quantitative Survey and Discrete Choice Experiment in Eswatini, Kenya, and South Africa

  2023cites this paper
• Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy

  2023cites this paper
• A multicompartment population PK model to predict tenofovir and emtricitabine mucosal tissue concentrations for HIV prevention

  2023cites this paper
• Reply to Authors.

  2023cites this paper
• Advances in the treatment and prevention of HIV: what you need to know.

  2023cites this paper
• Viral dissemination and immune activation modulate antiretroviral drug levels in lymph nodes of SIV-infected rhesus macaques

  2023cites this paper
• Single-nucleotide polymorphisms in ABC drug transporters alter expression and circulating tenofovir in healthy South African women exposed to pre-exposure prophylaxis.

  2023cites this paper
• Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial

  2023cites this paper
• Performance of Multiple Adherence Measures for pre-exposure Prophylaxis (PrEP) Among Young Women in Kenya

  2023cites this paper
• Evaluation of Sex Differences in Preclinical Pharmacology Research: How Far Is Left to Go?

  2023cites this paper
• HIV Pharmacology Data Repository (PDR): Setting the New Information Sharing Standard for Pharmacokinetic Studies

  2023cites this paper
• Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates

  2023cites this paper
• The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities.

  2023cites this paper
• A Patient-Centered, Combination Intervention to Support Adherence to HIV Pre-exposure Prophylaxis During Pregnancy and Breastfeeding: A Randomized Pilot Study in Malawi

  2023cites this paper
• Equipping providers to offer novel MPTs: Developing counseling messages for the Dual Prevention Pill in clinical studies and beyond

  2023cites this paper
• Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabine

  2023cites this paper
• Factors associated with retention on pre-exposure prophylaxis among female sex workers in Kigali, Rwanda

  2023cites this paper
• Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men.

  2022cites this paper
• Ultra-long-acting refillable nanofluidic implant confers full protection against SHIV infection in non-human primates

  2022cites this paper
• Episodic Use of Pre-Exposure Prophylaxis Among Young Cisgender Women in Siaya County, Kenya

  2022cites this paper
• Human Immunodeficiency Virus Treatment and Prevention for Pregnant and Postpartum Women in Global Settings.

  2022cites this paper
• Self-reported and pill count measures of adherence to oral HIV PrEP among female sex workers living in South-Western Uganda

  2022cites this paper
• Trajectories of Oral PrEP Adherence Among Young Kenyan Women: Implications for Promoting Effective PrEP Use

  2022cites this paper
• A novel “HIV salience and Perception” scale is associated with PrEP dispensing and adherence among adolescent girls and young women in Kampala, Uganda

  2022cites this paper
• Female Genital Fibroblasts Diminish the In Vitro Efficacy of PrEP against HIV

  2022cites this paper
• A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Trial of Radiopaque Islatravir-Eluting Subdermal Implants for Pre-exposure Prophylaxis Against HIV-1 Infection

  2022cites this paper
• U.S. Black Women and Human Immunodeficiency Virus Preexposure Prophylaxis Implementation.

  2022cites this paper
• Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue

  2022influential citation
• A qualitative exploration to understand barriers and facilitators to daily oral PrEP uptake and sustained adherence among HIV‐negative women planning for or with pregnancy in rural Southwestern Uganda

  2022cites this paper
• Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis.

  2022cites this paper
• Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

  2022cites this paper
• Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.

  2022cites this paper
• Genital immune cell activation and tenofovir gel efficacy: a case-control study.

  2022cites this paper
• UK guideline for the use of HIV post‐exposure prophylaxis 2021

  2022cites this paper
• Special Collection: A pioneer in antiviral drug discovery and development: Commemorating John Martin-Review

  2022cites this paper
• Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.

  2022cites this paper
• The CHARISMA Randomized Controlled Trial: A Relationship-Focused Counseling Intervention Integrated Within Oral PrEP Delivery for HIV Prevention Among Women in Johannesburg, South Africa

  2022cites this paper
• ‘If the Partner Finds Out, then there’s Trouble’: Provider Perspectives on Safety Planning and Partner Interference When Offering HIV Pre-exposure Prophylaxis (PrEP) to Women Experiencing Intimate Partner Violence (IPV)

  2022cites this paper
• CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women

  2022cites this paper
• Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel

  2022cites this paper
• Preferences for HIV Preexposure Prophylaxis Products Among Black Women in the U.S.

  2022cites this paper
• Dapivirine Vaginal Ring for HIV Prevention in Women in South Africa

  2022cites this paper